← Leaderboards
Oyebimpe Oluyemisi Adesina
University Of California At Davis
$925,439
Attributed
$925,439
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $187.2K · FY2021–25$200K$150K$100K$50K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$925,439 · 1
By mechanism
K23$925,439 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California At Davis
Same institution · by research overlap
- Kristin Nicole Grimsrud$1,702,320
- Wei Yao$1,815,202
- Chengji Zhou$8,946,869
- Danika L Bannasch$3,249,648
- David G Amaral$36,802,574
Others in their field
Other Emerging Leaders on “Acute”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$51,003,204
- Julie Ake · National Institute Of Allergy And Infectious Diseases$41,692,120
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$29,269,420
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
Research focus
AcuteAdolescentAdherenceAdverse EventAffectAlendronateAnalgesicsAdultBiological MarkersBisphosphonateBlood FlowBoneBone DensityBone DiseasesBone NecrosisBone PainBone ResorptionArthralgiaBone TurnoverCaliforniaCareerChildChildhoodChronic
Grant awards (5)
A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease$177,907
K23 · FY2025 · HL · contact PI
A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease$186,910
K23 · FY2024 · HL · contact PI
A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease$187,234
K23 · FY2023 · HL · contact PI
A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease$187,234
K23 · FY2022 · HL · contact PI
A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease$186,154
K23 · FY2021 · HL · contact PI